- Home
- SCNX vs CANF Comparison
SCNX vs CANF Comparison
Compare SCNX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- CANF
- Stock Information
- Founded
- SCNX 2010
- CANF 1994
- Country
- SCNX United States
- CANF Israel
- Employees
- SCNX N/A
- CANF N/A
- Industry
- SCNX Other Pharmaceuticals
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- CANF Health Care
- Exchange
- SCNX Nasdaq
- CANF Nasdaq
- Market Cap
- SCNX 14.4M
- CANF 14.8M
- IPO Year
- SCNX 2020
- CANF N/A
- Fundamental
- Price
- SCNX $0.98
- CANF $1.07
- Analyst Decision
- SCNX
- CANF Strong Buy
- Analyst Count
- SCNX 0
- CANF 2
- Target Price
- SCNX N/A
- CANF $14.00
- AVG Volume (30 Days)
- SCNX 129.8K
- CANF 137.8K
- Earning Date
- SCNX 08-10-2025
- CANF 04-14-2025
- Dividend Yield
- SCNX N/A
- CANF N/A
- EPS Growth
- SCNX N/A
- CANF N/A
- EPS
- SCNX N/A
- CANF N/A
- Revenue
- SCNX $146,901.00
- CANF $674,000.00
- Revenue This Year
- SCNX N/A
- CANF $461.72
- Revenue Next Year
- SCNX N/A
- CANF N/A
- P/E Ratio
- SCNX N/A
- CANF N/A
- Revenue Growth
- SCNX N/A
- CANF N/A
- 52 Week Low
- SCNX $0.69
- CANF $0.98
- 52 Week High
- SCNX $23.77
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- CANF 39.89
- Support Level
- SCNX N/A
- CANF $1.02
- Resistance Level
- SCNX N/A
- CANF $1.09
- Average True Range (ATR)
- SCNX 0.00
- CANF 0.04
- MACD
- SCNX 0.00
- CANF -0.00
- Stochastic Oscillator
- SCNX 0.00
- CANF 6.67
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).